AcquisitionOther
Fusion Pharmaceuticals Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Fusion Pharmaceuticals Inc. -> target · $21.00
The Arrangement complements AstraZenecas leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced program, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (
Open source record (SEC) ↗